Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
Status:
Completed
Trial end date:
2018-07-02
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label interventional study of ingenol mebutate 0.015% in solid
organ transplant recipients. The investigators plan to treat 20 subjects, 10 kidney
transplant recipients and 10 lung transplant recipients. The investigators have selected
these two populations as the represent the spectrum of solid organ transplantation: kidney
transplant recipients are the largest transplant population, but have lower levels of
immunosuppression and skin cancer risk. Lung transplant recipients have the highest burden of
skin cancer and actinic keratoses.